News & Views | Published:


Sustainability and affordability of cancer drugs: a novel pricing model

Nature Reviews Clinical Oncologyvolume 15pages405406 (2018) | Download Citation

The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    International Agency for Research on Cancer & World Health Organization. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. IARC (2017).

  2. 2.

    Luengo-Fernandez, R. et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14, 1165–1174 (2013).

  3. 3.

    Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–2013. BMJ 359, j4530 (2017).

  4. 4.

    Chandra, A., Shafrin, J. & Dhawan, R. Utility of cancer value frameworks for patients, payers, and physicians. JAMA. 315, 2069–2070 (2016).

  5. 5.

    OncLive. Enzalutamide pricing debate goes to Washington. OncLive (2016).

  6. 6.

    Orphan Druganaut Blog. What is the price of orphan drug ruxolitinib? Orphan Druganaut Blog (2012).

  7. 7.

    DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).

  8. 8.

    Prasad, V. & Mailankody, S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern. Med. 177, 1569–1575 (2017).

  9. 9.

    Marseille, E. et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull. World Health Organ. 93, 118–124 (2015).

  10. 10.

    American Society of Clinical Oncology. American Society of Clinical Oncology position statement on addressing the affordability of cancer drugs. ASCO (2017).

Download references

Author information


  1. Erasmus School of Health Policy & Management and Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, Netherlands

    • Carin A. Uyl-de Groot
  2. Department of Haematology, Erasmus University Medical Center, Rotterdam, Netherlands

    • Bob Löwenberg


  1. Search for Carin A. Uyl-de Groot in:

  2. Search for Bob Löwenberg in:

Competing interests

C.U.-d.G. has received unrestricted grants for research within the Erasmus University from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Genzyme, Gilead, Janssen-Cilag, Merck, Roche and Sanofi. B.L. has received personal fees from Agros Pharmaceuticals, Astellas, ASTEX, Celgene, Clear Creek Bio, F. Hoffman-La Roche, Novartis and Seattle Genetics.

Corresponding author

Correspondence to Carin A. Uyl-de Groot.

Supplementary information

About this article

Publication history


Issue Date


Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing